Heterotopic heart transplantation: where do we stand?

被引:10
|
作者
Flecher, Erwan [1 ]
Fouquet, Olivier [2 ]
Ruggieri, Vito Giovanni [1 ]
Chabanne, Celine [1 ]
Lelong, Bernard [1 ]
Leguerrier, Alain [1 ]
机构
[1] Rennes Univ Hosp, Dept Cardiothorac & Vasc Surg, Rennes, France
[2] Angers Univ Hosp, Dept Cardiac Surg, Angers, France
关键词
Heterotopic; Orthotopic; Transplantation; FIXED PULMONARY-HYPERTENSION; CIRCULATORY SUPPORT; HEMODYNAMICS; PIONEER;
D O I
10.1093/ejcts/ezt136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Orthotopic heart transplantation (OHT) is a well established and commonly utilized procedure for end-stage heart failure patients. Heterotopic heart transplantation (HHT) is a surgical procedure that allows the graft to be connected to the native heart in a parallel fashion. The main advantage of HHT is to assist the patient's native heart and to maintain circulation in the cases of severe acute rejection. HHT has also been proposed to overcome pulmonary hypertension, to increase the size of the donor pool and to decrease waiting times without increasing morbidity caused by the procedure. However, only a few papers have reported the short- or long-term results of HHT, and most of these studies have included <30 cases. OHT remains the standard technique and is preferable whenever the patient meets the current criteria and a suitable organ is available. HHT is far less useful than in the past because of the major advances in immunosuppression therapy and the development of long-term mechanical circulatory support. This study reviews the origin of HHT and discusses clinical developments, including their advantages and disadvantages.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 50 条
  • [11] Islet transplantation: where do we stand now?
    Hirshberg, B
    Rother, KI
    Harlan, DM
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2003, 19 (03) : 175 - 178
  • [12] Biomarkers in kidney transplantation: Where do we stand?
    Lopez-Abad, A.
    Piana, A.
    Prudhomme, T.
    Marco, B. Banuelos
    Donmez, M. I.
    Pecoraro, A.
    Boissier, R.
    Campi, R.
    Breda, A.
    Territo, A.
    ACTAS UROLOGICAS ESPANOLAS, 2024, 48 (06): : 407 - 409
  • [13] Advanced heart failure: Where do we stand?
    Tousoulis, Dimitris
    HELLENIC JOURNAL OF CARDIOLOGY, 2019, 59 (06) : 303 - 305
  • [14] Statins in Heart Failure—Where Do We Stand?
    Kristopher S. Lyons
    Gary E. McVeigh
    Mark T. Harbinson
    Cardiovascular Drugs and Therapy, 2011, 25 : 99 - 104
  • [15] Uterus transplantation:: where do we stand today and where should we go?
    Brannstrom, Mats
    Wranning, Caiza Almen
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (04) : 427 - 429
  • [16] Living donor liver transplantation: where do we stand and where are we going?
    Lu, Hao
    Lu, Ling
    Zhang, Feng
    Zhai, Yuan
    Wang, Xuehao
    HEPATOBILIARY SURGERY AND NUTRITION, 2016, 5 (02) : 141 - 144
  • [17] Late Sodium Current of the Heart: Where Do We Stand and Where Are We Going?
    Horvath, Balazs
    Szentandrassy, Norbert
    Almassy, Janos
    Dienes, Csaba
    Kovacs, Zsigmond Mate
    Nanasi, Peter P.
    Banyasz, Tamas
    PHARMACEUTICALS, 2022, 15 (02)
  • [18] Cell transplantation for cardiac regeneration: where do we stand?
    van den Bos, E. J.
    van der Giessen, W. J.
    Duncker, D. J.
    NETHERLANDS HEART JOURNAL, 2008, 16 (03) : 88 - 95
  • [19] Pancreas transplantation, antibodies and rejection: where do we stand?
    de Kort, Hanneke
    Roufosse, Candice
    Bajema, Ingeborg M.
    Drachenberg, Cinthia B.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2013, 18 (03) : 337 - 344
  • [20] Renal transplantation 2004: where do we stand today?
    Ponticelli, C
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (12) : 2937 - 2947